Your browser doesn't support javascript.
loading
Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC.
Evans, Rachel; Lee, Kelvin; Wallace, Paul K; Reid, Mary; Muhitch, Jason; Dozier, Askia; Mesa, Circe; Luaces, Patricia L; Santos-Morales, Orestes; Groman, Adrienne; Cedeno, Carlos; Cinquino, Aileen; Fisher, Daniel T; Puzanov, Igor; Opyrchal, Mateusz; Fountzilas, Christos; Dai, Tong; Ernstoff, Marc; Attwood, Kristopher; Hutson, Alan; Johnson, Candace; Mazorra, Zaima; Saavedra, Danay; Leon, Kalet; Lage, Agustin; Crombet, Tania; Dy, Grace K.
Afiliación
  • Evans R; Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
  • Lee K; Department of Medicine Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.
  • Wallace PK; Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
  • Reid M; Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
  • Muhitch J; Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
  • Dozier A; Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
  • Mesa C; Centro de Immunologia Molecular, La Habana, Cuba.
  • Luaces PL; Centro de Immunologia Molecular, La Habana, Cuba.
  • Santos-Morales O; Centro de Immunologia Molecular, La Habana, Cuba.
  • Groman A; Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
  • Cedeno C; Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
  • Cinquino A; Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
  • Fisher DT; Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
  • Puzanov I; Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
  • Opyrchal M; Department of Medicine Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.
  • Fountzilas C; Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
  • Dai T; Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
  • Ernstoff M; National Cancer Institute (NCI) Division of Cancer Treatment and Diagnosis, Bethesda, MD, United States.
  • Attwood K; Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
  • Hutson A; Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
  • Johnson C; Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
  • Mazorra Z; Centro de Immunologia Molecular, La Habana, Cuba.
  • Saavedra D; Centro de Immunologia Molecular, La Habana, Cuba.
  • Leon K; Centro de Immunologia Molecular, La Habana, Cuba.
  • Lage A; Centro de Immunologia Molecular, La Habana, Cuba.
  • Crombet T; Centro de Immunologia Molecular, La Habana, Cuba.
  • Dy GK; Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
Front Oncol ; 12: 958043, 2022.
Article en En | MEDLINE | ID: mdl-35992783
Background: CIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy which has shown survival benefit as a switch maintenance treatment after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC). The primary objective of this trial is to establish the safety and recommended phase II dose (RP2D) of CIMAvax-EGF in combination with nivolumab as second-line therapy for NSCLC. Methods: Patients with immune checkpoint inhibitor-naive metastatic NSCLC were enrolled using a "3+3" dose-escalation design. Toxicities were graded according to CTCAE V4.03. Thirteen patients (one unevaluable), the majority with PD-L1 0%, were enrolled into two dose levels of CIMAvax-EGF. Findings: The combination was determined to be safe and tolerable. The recommended phase 2 dose of CIMAvax-EGF was 2.4 mg. Humoral response to CIMAvax-EGF was achieved earlier and in a greater number of patients with the combination compared to historical control. Four out of 12 evaluable patients had an objective response.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza